Evaluating Modes of Influenza Transmission (EMIT-2): Challenges of a Controlled

Human Influenza Virus Infection Transmission Trial (CHIVITT)

Jianyu Lai[1], Hamed Sobhani[2], Kristen K. Coleman[1], S.-H. Sheldon Tai[1], Filbert Hong[1], Isabel

Sierra Maldonado[1], Yi Esparza[1], Kathleen M. McPhaul[1], Shengwei Zhu[2], Don L. DeVoe[2,3],

Justin R. Ortiz[4], Shuo Chen[5], Temima Yellin[6], Juan Manuel Carreno[6], Florian Krammer[6-9],

Benjamin J. Cowling[10], Aubree Gordon[11], Wilbur H. Chen[4], Jelena Srebric[2], and Donald K.

Milton[1,3*] for the EMIT-2 Study Team

[1] Department of Global, Environmental, and Occupational Health, School of Public Health,

University of Maryland, College Park, MD, USA

[2] Department of Mechanical Engineering, University of Maryland, College Park, MD, USA

[3] Fischell Institute for Biomedical Devices, University of Maryland, College Park

[4] Center for Vaccine Development and Global Health, University of Maryland School of

Medicine, Baltimore, MD, USA

[5] Department of Epidemiology and Public Health, University of Maryland School of Medicine,

Baltimore, MD, USA

[6] Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[7] Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount

Sinai, New York, NY, USA

[8] Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at

Mount Sinai, New York, NY, USA

[9] Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University

of Vienna, Vienna, Austria

[10] School of Public Health, The University of Hong Kong, Hong Kong Special Administrative

Region, China

[11] School of Public Health, University of Michigan, Ann Arbor, MI, USA

*Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive,

College Park, MD 20742, USA email: dmilton@umd.edu; phone: 301-405-0389

Abstract

Background: The relative importance of influenza transmission via inhalation (airborne), direct

deposition (spray), and contact (touch) remains poorly understood. We implemented a controlled

human influenza virus infection transmission trial to study transmission pathways.

Methods: We established a quarantine hotel with individual rooms for participants and recruited

healthy Recipients for two-week cohort stays. We recruited Donors with community-acquired

influenza virus infection, confirmed by qRT-PCR. Donors and Recipients interacted in a room

with limited ventilation and controlled humidity. We collected ambient and personal bioaerosol,

Donor exhaled breath, and fomite surface swab samples. We analyzed aerosol and surface swab

samples using dPCR and florescent focus assays, and sera by hemagglutination inhibition (HAI)

assay and enzyme-linked immunosorbent assay.

Results: We enrolled four Recipient cohorts (one Feb 2023 and three Jan-Feb 2024) and

recruited Donors for two 2024 cohorts. We exposed 11 Recipients (mean age: 36; 55% female)

to 5 Donors (mean age: 21; 80% female; two H1N1, three H3N2) for 82 Donor-hours. Among 16

breath samples from Donors, 7 G-II fine (<5µm), one G-II coarse (≥5µm), and 2 of 24 NIOSH

ambient air (one ≥4µm and one 1-4µm) tested PCR positive. We cultured influenza virus from 1

G-II fine aerosol and 1 of 23 surface swab samples. No Recipient developed influenza-like

illness or PCR-positive swabs or saliva. Admission sera for 8 of 11 Recipients had HAI titers

≤10, and 9 of 11 had stronger binding antibody responses than respective Donors, against

vaccine strains corresponding to Donor viruses.

Conclusions: We successfully recruited community-acquired influenza Donors and exposed

healthy Recipients under controlled conditions. However, the unpredictable timing of influenza

seasons, a small eligible Recipient pool, pre-existing immunity, and limited virus shedding by

53   Donors posed significant challenges. Addressing these factors will be critical for optimizing

54   future study designs and improving our understanding of influenza transmission dynamics.

Author Summary

We designed a controlled intervention trial to identify whether influenza virus spreads between people mainly by breathing contaminated air (airborne/inhalation transmission), spray (direct deposition) of large semi-ballistic droplets at close range, or touch (contact). Understanding how influenza spreads can help improve strategies for prevention, vaccine development, and public health policies. We recruited four cohorts of healthy volunteer Recipients to stay in a quarantine hotel for two weeks. We asked them to interact in a poorly ventilated room with Donors who had recently become infected with influenza virus during their normal activities. We successfully recruited a total of five Donors to interact with 11 Recipients over the course of two quarantine cohorts. We detected small quantities influenza virus in Donor exhaled breath, in room air, and on surfaces, and none of the Recipients became infected. Unpredictability of the influenza season, a small pool of eligible Recipients, Recipient immunity, and Donors more than 24-hour post symptom onset with low rates of shedding presented significant challenges. These results suggest that new designs capable of bringing together larger numbers of Donors, early in the course of infection, with susceptible Recipients will be required to increase the odds of observing transmission.

Introduction

In a typical year seasonal influenza is associated with hundreds of thousands of hospitalizations and tens of thousands of deaths in the US [1]. Although the 2009 pandemic influenza virus had a broadly similar severity profile to seasonal influenza [2–4], the three previous pandemics in the 20th century were associated with much greater morbidity and mortality [5]. Influenza is therefore responsible for a considerable burden of disease in the US and globally, and control of influenza is a public health priority. The effective reproductive number of seasonal influenza is estimated to be around 1.3 at the start of an influenza season, meaning that we expect an average of 1.3 secondary cases from an infected person, depending on the environment and number of people whom they come into contact [6].

It is now well established that humans shed infectious virus into fine particle aerosols both when coughing and also when simply breathing [7]. A post-hoc analysis of household studies suggests that viral aerosols play an important role in transmission, with half of influenza transmissions in households occurring via inhalation [8]. In April 2024, the World Health Organization released a technical consultation report and defined the modes of respiratory pathogen transmission as airborne transmission/inhalation, direct deposition, and contact (direct and indirect) corresponding to a previously proposed transfer-process categorization: inhalation, spray, and touch transmission, respectively [9,10]. Despite extensive research, the relative importance of these transmission modes remains poorly understood, posing challenges to the development, implementation, and prioritization of effective control strategies.

In 2013, a randomized controlled trial (RCT) of human challenge-transmission, Evaluating

Modes of Influenza Transmission (EMIT-1), was conducted to evaluate the relative importance

of these transmission modes [11,12]. EMIT-1, using volunteers intranasally inoculated with 10^5

50% tissue culture infectious doses (TCID$_{50}$) influenza virus as Donors, failed to meet the

expected secondary attack rate (SAR) and only one serology-confirmed asymptomatic, PCR-

negative infection was identified in a Control Recipient [12]. Post-hoc analyses revealed that

Donors intranasally inoculated with influenza virus had mild symptoms and minimal shedding of

virus in exhaled breath compared to symptomatic community-acquired cases [11] as well as a

mildly symptomatic influenza cases from a longitudinal cohort [13]. These findings suggested

that a controlled human influenza virus transmission trial (CHIVITT) with community-acquired

cases as Donors would be needed to study the dynamics of influenza transmission.

Here, we describe a CHIVITT incorporating community-acquired cases using a behavioral and

personal protective equipment intervention in a low air hygiene environment as a tool to

understand the pathway of influenza virus transmission.

Results

A schematic of the study design is shown in Figure 1a and the timeline of two cohorts is shown

in Figure 1b.

 Study cohort and study population

By January 3, 2024, we recruited 80 potential Recipients into a study registry (Figure 2). A total

of 467 potential Donors expressed interest, with six ultimately admitted to the quarantine facility

(Figure 3). Between 2023 and 2024, we ran four quarantine cohorts: one in 2023 (23a) and three

in 2024 (24a, 24b, 24c).

During the first two quarantines (23a and 24a) we enrolled 12 Recipients (4 in 23a and 8 in 24a)

but were unable to recruit naturally infected influenza Donors. Cohort 23a, delayed by the

coronavirus disease 2019 (COVID-19) pandemic until February 20 to March 5, 2023, included

one Intervention Recipient (IR) given a hand-hygiene and face shield intervention and three

Control Recipients (CRs). However, due to an early, short influenza season, we were unable to

recruit a naturally infected Donor. In Cohort 24a (Jan 3 to 16, 2024), we randomized eight

Recipients (four IRs and four CRs). One Donor recruited based on a rapid influenza test reported

by an outside facility later proved to be infected with a seasonal coronavirus (229E) and not

influenza virus.

The second two cohorts 24b and 24c included 11 Recipients and 5 naturally infected Donors. We

enrolled three IRs, five CRs and one Donor in cohort 24b (Jan 24 to Feb 6, 2024). We enrolled

one IR, two CRs, and four Donors in 24c (Feb 14 to 27, 2024). All Donors reported symptom

onset within the last 48 hours. However, later evidence indicated that one of the Donors (D24c-3)

had earlier onset. All tested positive for influenza A virus by a molecular test at recruiting sites

on the University of Maryland College Park campus. Among them, the Donor in 24b (D24b-1)

and two Donors in 24c (D24c-1 and D24c-2) were infected with H3N2, while the other two

Donors (D24c-3 and D24c-4) were infected with H1N1 influenza viruses.

Across all cohorts (23a, 24a, 24b, and 24c), the 23 Recipients were middle-aged adults, with a

mean age of 38 years. Male Recipients (61%) outnumbered females, although we enrolled a

slightly higher proportion of female Recipients (55%) in 24b and 24c. Nearly one-third (30%) of

Recipients received an influenza vaccine earlier in the same influenza season before enrolling in

quarantine (Table 1). Among the six Donors, most were female (83%) and young adults, with a

mean age of 22 years (Table 2).

Exposure Events and Activities

We conducted 23 exposure events involving influenza Donors, including 6 events in cohort 24b

and 17 events in cohort 24c. These events lasted between 111 and 250 minutes, totaling 82.2

cumulative influenza Donor hours. In 11 events, only one Donor was present, while the

remaining events included two Donors. Additionally, in cohort 24b, we ran two extra exposure

events with only Recipients present to monitor potential secondary transmission.

Environmental Conditions

Mechanical systems successfully maintained stable environmental conditions in the exposure

event room during exposure events. The indoor air temperature remained within 22-25°C, and

relative humidity ranged between 20-45% (Figure 4). The ventilation rate was approximately

0.25-0.5 air changes per hour (detailed ventilation results are presented in a recent publication

[14]).

CO_2 concentrations in the exposure event room increased rapidly during exposure events, as

occupants were the sole CO_2 source, and returned toward the background level (~420 ppm) after

the exposure event. In 24b, with 11 occupants, CO_2 levels ranged between 460-5300 ppm, while

in 24c, with 7 occupants, CO_2 levels were lower, ranging from 430 to 2400. These fluctuations in

CO_2 correlated with variations in temperature and relative humidity. CO_2 levels in the corridor

remained relatively stable near background concentrations, with minor fluctuations caused by

occasional human traffic and the opening of the exposure event room doors.

Viral Shedding and Environmental Contamination by Donors

Exhaled Breath Aerosol Samples

Using the G-II, we collected 16 exhaled breath aerosol samples from five influenza Donors.

During each 30-minute collection period, Donors coughed and sneezed spontaneously, with

cough counts ranging from 0 to 16 (median: 0) and sneeze counts from 0 to 1 (median: 0)

(Supplementary Table 1).

Among these exhaled breath aerosol samples, we detected viral RNA in seven (44%) fine (<5µm,

range: 79 – 8.9x10^3 copies per 30-minute sample) and one (6%) coarse (≥5µm, 53 copies per 30-

minute sample) aerosol sample. One fine aerosol sample was culture positive, with an infectious

viral load of 147 focus forming units (FFU) per 30-minute sample (Figures 5–6). The viral RNA

load in breath aerosol samples fluctuated over time and did not follow a clear pattern across

Donors (Figures 5–6).

The only culture-positive breath aerosol sample came from the Donor in 24b (D24b-1) on their

last day in quarantine, when they coughed the most during the 30-minute exhaled breath

sampling (six times) and shed their highest breath aerosol viral RNA load (405 copies per 30-

minute sample). Eight Recipients were exposed for four hours on this day, totaling 32 Recipient-

exposure hours.

Mid-turbinate swabs and Saliva

We collected 18 mid-turbinate swabs (MTS) samples and 18 saliva samples from Donors. All

MTS samples contained detectable viral RNA (range: $5.32 \times 10^4 - 3.91 \times 10^8$ genome copies/swab),

and 11 (61%) were culture positive with viral loads from 40 to 8.7×10^4 FFU/swab. Among saliva

samples, 15 (83%) contained detectable viral RNA (range: $67 - 4.37 \times 10^7$ copies/mL); however,

none were culture positive (Figures 5–6).

Ambient and Personal Bioaerosol Sampling

We collected two ambient air samples and two personal breathing zone air samples during each

of 12 afternoon exposure events (one per day), resulting in a total of 24 ambient and 24 personal

samples. The personal samples included 12 from IRs and 12 from CRs.

Among the ambient samples, we detected viral RNA in one sample collected at sitting breathing

level height (129cm) in the 1-4 µm size fraction, with a total load of 188 RNA copies/m^3. One

other ambient sample, collected at standing breathing level height (150cm), contained detectable

viral RNA in the >4 µm size fraction (62 RNA copies/m^3). None of the personal bioaerosol

samples contained detectable viral RNA by dPCR.

Surface Swab Viral Load

209 We collected 23 surface swabs from fomites used in exposure events with a Donor. Among

210 these, one sample, collected during the third exposure event of the Donor's second day in

211 quarantine (24b), contained virus detected by dPCR and culture (total viral load of 454 RNA

212 copies and 20 FFU).

Symptoms Reported by Donors and Recipients

Donors reported varying levels of symptom severity across a range of individual symptoms

(Figure 7a). Throughout the quarantine period, total symptom scores fluctuated for the Donor in

24b (D24b-1), but generally declined for Donors in cohort 24c, though the rate of decline

differed among Donors (Figure 7b).

Recipients sporadically reported individual symptoms, with overall symptom severity lower than

that of Donors. Malaise was the most frequently reported symptom (Figure 8a). Total symptom

scores fluctuated over time, with most Recipients reporting more symptoms after exposure to a

Donor (Figure 8b). Three Recipients reported symptoms only on days with exposure events but

not afterward. R24b-Ctl4 in cohort 24b recorded the highest total symptom score (10) three days

after exposure to the Donor (Figure 8b).

Recipient Post-Exposure PCR and Culture

We collected a total of 73 post-exposure MTS and saliva samples from Recipients. In cohort

24b, each Recipient provided five MTS and saliva samples on days 1 through 5 following their

first exposure event. In cohort 24c, each provided 11 on days 1 through 11 following their first

exposure event. None of the samples tested positive by dPCR.

Serology from Donors and Recipients

Consistent with qRT-PCR test results, hemagglutination inhibition (HAI) titers for Donors

measured at admission and follow-up confirmed three H3N2 (D24b-1 from cohort 24b; D24c-1

and D24c-2 from cohort 24c) and two H1N1 (D24c-3 and D24c-4 from cohort 24c) infections

(Figure 9–10).

Among the exposed Recipients, 8 out of 11 had low HAI titers (≤10) at admission against the

vaccine strains corresponding to the Donor strains, including 6 out of 8 in cohort 24b, 2 out of 3

in cohort 24c (Figures 9–10), and one of the two vaccinated for the current season. However,

none of the Recipients showed a four-fold increase in HAI titers against the vaccine strains from

admission to follow-up, except for one Recipient in cohort 24b (R24b-Ctl3), who responded to

all vaccine strains and reported having received an influenza vaccine two days after discharge

from quarantine.

The enzyme-linked immunosorbent assay (ELISA) results were generally consistent with the

HAI titer findings, as none of the Recipients showed a four-fold increase in area under the curve

(AUC) values against vaccine strains HAs corresponding to the Donor infections, including the

Recipient who received an influenza vaccine after quarantine (Supplementary Figures 1–2).

However, ELISA results indicated higher AUC values in Recipients than in Donors at baseline.

In cohort 24b, all eight Recipients had higher AUC values at admission compared to the Donor.

Similarly, in cohort 24c, one of three Recipients had a much higher AUC value than their Donor

counterparts at admission.

Discussion

This study explored a novel framework for investigating human influenza virus transmission

using community-acquired Donors under controlled conditions. We successfully recruited

Donors with naturally acquired influenza and conducted exposure events in a regulated

environment. However, despite enrolling Donors within 48 hours of symptom onset, optimizing

conditions for potential transmission, and observing limited pre-existing immunity based on HAI

titers, no Recipient developed a PCR-confirmed influenza virus infection, a serologic response,

or influenza-like illness.

The Donors in our present study shed less virus than previously reported for community-

acquired influenza cases recruited from the same college campus. In a previous report [7], 76%

of fine aerosol samples and 40% of coarse aerosol samples tested PCR positive, with 30% of fine

aerosol samples culturing positive by focus assay. In contrast, we detected PCR-positive virus in

only 44% of fine and 6% of coarse aerosol samples, with just one (6%) fine aerosol sample

culturing positive by focus assay. Coughing has been identified as a key factor associated with

higher viral RNA levels in breath aerosols [7]. Our Donors generally coughed less during sample

collection, with a median cough count of 0 (interquartile range: 0–4), compared to 18

(interquartile range: 5–39) reported in previous influenza cases [7]. The lower overall

contagiousness of our Donors may be a key reason why no secondary transmission was observed

in this study. For future studies, it may be necessary to refine inclusion criteria to identify and

enroll Donors earlier in the course of infection when they may be most contagious, such as

requiring onset within 24 rather than 48 hours.

The absence of PCR-confirmed infections among Recipients may also be attributable to pre-

existing immunity. Although most of the Recipients had low HAI titers (≤10) against the vaccine

strains corresponding to Donor viruses, our ELISA results showed that they had higher AUC

values against these strains at baseline than did Donors, suggesting potential pre-existing

immunity from prior infections or vaccinations. In the previous EMIT-1 challenge study,

enrollment began with a registry of 496 volunteers with HAI titers ≤10 at screening who reported

not having had a seasonal influenza vaccine in the last 3 years [12]. In contrast, our current study

had a much smaller registry pool (80 volunteers), and over one-fourth of Recipients who were

later exposed to an influenza Donor had baseline HAI titers >10. Additionally, nearly one-third

of Recipients received an influenza vaccine during the same influenza season as the quarantine,

including two who were later exposed to an influenza Donor. Given that our Recipients were

middle-aged adults, they may have had greater cumulative exposure to influenza virus infections

and vaccinations than our Donors, further contributing to broader immunity. Studies have shown

that older adults are more likely than children to develop enhanced pre-existing cross-reactive

antibodies due to prior infections and vaccinations [15].

Challenges of a CHIVITT study & Lessons Learned

The unpredictable timing and duration of influenza seasons pose a major challenge in conducting

a CHIVITT using Donors with community-acquired infection. The inability to recruit an

influenza virus-positive Donor in 2023, due to an early and short influenza season, highlighted

the need to prepare for potential quarantines from November through early March to capture

both early and late influenza seasons, as we did in for the 2023-24 influenza season. The

resulting prolonged hotel rental including months without influenza activity, added considerable

expense.

Pre-existing immunity among Recipients presents another challenge. More than a quarter of

Recipients had HAI titers >10 against the vaccine strains corresponding to Donor viruses at

baseline, suggesting some had prior exposure to the circulating influenza virus strains and 80%

had evidence for some cross-reacting immunity. This reduced the number of highly susceptible

individuals, limiting opportunities to observe transmission events. Future CHIVITT studies will

need a large Recipient registry of younger potential volunteers with greater baseline

susceptibility, and to actively screen for recent exposure to vaccines and infection immediately

before quarantine enrollment.

The study was originally designed to evaluate the mode of transmission using high and low air

hygiene conditions in addition to a hand-hygiene and face-mask intervention. Based on an

expected SAR of 20% under low air hygiene conditions without the hand-hygiene and face-

shield intervention, we estimated that we would need 18 Recipients per quarantine cohort for 3

sets of paired high and low air hygiene cohorts to achieve sufficient power to detect the expected

reduction in SAR (Detailed in Supplementary Materials). However, the quarantine hotel could

only accommodate 16 recipients per cohort and at best, we were only able to enroll 8 recipients

in our largest cohort. Based on our experience, we estimate that about a third of Registry

members will remain eligible and available to enroll in a quarantine event. Of those who enter

quarantine a quarter will be discharged early, often due to a respiratory infection. If we include

screened for preexisting immunity at the time of admission , we expect that 60% would need to

be excluded because of high HAI or ELISA AUC. Therefore, to fill each quarantine cohort with

16 people we would need a registry of 160 people and the six quarantines we proposed would

require a registry of 960 eligible volunteers –12 times the size of our registry at the start of the

January 2024 quarantines.

Conclusions

We demonstrated that it is feasible to recruit Donors with new onset community-acquired

influenza virus infections and expose Recipients under highly controlled conditions. However,

the unpredictable timing of influenza seasons, limited shedding by Donors by the time they reach

the quarantine hotel, pre-existing immunity among enrolled Recipients, and a limited pool of

eligible Recipients presented significant challenges. Our work suggests that a successful

CHIVITT using community acquired Donors will require getting Donors into exposure events

quickly while still potentially contagious, and enrolling larger numbers of immunologically naïve

(i.e., younger adult) Recipients.

Materials and Methods

Overview of Study Design

In this CHIVITT our study population consisted of two groups of volunteers – healthy volunteer

Recipients without evidence of respiratory infection on a multiplex molecular test, and Donors

with recent-onset community-acquired influenza virus infection. Recipients stayed in a

quarantine hotel for two weeks, while Donors stayed two to five days. Donors and Recipients

interacted during exposure events in an exposure event room sealed to provide low ventilation.

We equipped the exposure event room with dehumidifiers to maintain low relative humidity. The

Recipients were randomly assigned to intervention Recipient (IR) or control Recipient (CR)

groups. IRs wore a face shield to interrupt direct deposition transmission and sanitized their

hands every 15 minutes to interrupt direct and indirect contact (touch) transmission; IR and CR

groups in each exposure event received similar risk from inhalation of infectious respiratory

particle aerosols. CRs did not wear face shield or sanitize their hands during the exposure event;

they would have been exposed to all modes of transmission (Figure 1).

Study Setting

This study took place in a dedicated, isolated floor of a hotel in Baltimore, Maryland, USA that

had been used as a quarantine hotel for COVID-19. We equipped 18 rooms for individually

housing up to 16 Recipients and 2 Donors.

Volunteer Recruitment

We recruited healthy volunteers aged 18 through 49 to enroll in a Recipient registry. Registry

members who remained eligible, available, and willing to commit to a two-week stay in the hotel

quarantine environment were admitted as Recipients at the start of each cohort study.

Concurrently, community members aged 18 through 59 with PCR-confirmed influenza virus

infection and symptom onset within 48 hours were recruited and admitted to the quarantine

facility as Donors. Eligibility criteria of Donors and Recipients are detailed in the Supplementary

Materials, Sections III and IV.

Randomization, Concealment, and Blinding

Recipients were randomly assigned to either the intervention group, receiving a hand hygiene

and face shield intervention (HH+FS) as an IR, or the control group, receiving no intervention as

a CR. We used randomization tables generated by a statistician, which were uploaded into the

randomization module in REDCap (Research Electronic Data Capture) [16] to assign Recipients.

REDCap was also used for data collection and management for this study.

Recipients and staff were unaware of the intervention assignment at enrollment; however,

concealment during the study was not possible due to the nature of the intervention. All research

nurses who collected biological samples and laboratory technicians who conducted PCR and

serologic assays were blinded to the Recipients' assignments.

Exposure Event

Structured activities were organized to encourage interaction between Recipients and Donors in

the exposure event room. Volunteers engaged in a variety of activities together, ranging from

physically demanding exercises such as yoga and dancing to more relaxed activities like solving

puzzles and watching movies. Each exposure event included activities that required participants

to handle a shared object. Two staff members were present at the exposure event room to

document and moderate the activities.

Symptom Monitoring

Both Donors and Recipients assessed their symptom twice daily by answering a survey, Modified Jackson Score, in their mobile device. They self-reported on a scale of 0 to 3 (0 = "no symptom", 1 = "Just noticeable", 2 = "Bothersome from time to time, but doesn't prevent me from doing activities", and 3 = "Bothersome most or all the time, and prevents me from doing activities") for the following symptoms: running nose, stuffy nose, sneezing, score throat, earache, malaise (tiredness, fatigue), headache, muscle and/or joint ache, chills, feverish, chest tightness, shortness of breath, and cough.

Biological Sample Collection

Mid-turbinate swabs (MTS) and saliva samples were collected daily from both Donors and Recipients. Blood samples were collected from both groups at three key time points: admission (at the start of the quarantine cohort, before any exposure event), discharge (at the end of the quarantine cohort), and a 28-day follow-up.

Exhaled breath sampling

Donors provided exhaled breath samples using a Gesundheit-II (G-II) exhaled breath aerosol sampler [17] on admission to the quarantine hotel and each morning thereafter. G-II samples were collected for a 30-minute period with the volunteers breathing normally, while shouting and singing loudly three times at 5, 15, 25 minutes, as previous described [18]. The G-II samples were categorized into two aerosol size fractions, including fine ($\leq$5 µm in diameter) and coarse (>5 µm in diameter) aerosols.

Ambient and personal bioaerosol sampling

To collect ambient air samples during exposure events, we used a ceiling track system to position NIOSH BC-251 bioaerosol sampling devices at sitting and standing breathing level heights (129cm and 150cm) in the designated common room (Figure 1). To measure personal, breathing zone influenza virus aerosol exposure, we mounted NIOSH BC-251 samplers to the front strap of small backpacks containing a compact SKC AirChek TOUCH pump (Figure 1a). Each sample pump was calibrated to 3.5 L/min and all samples were collected for 4 hours (840 liters). We sampled one 4-hour exposure event per day for both ambient and personal influenza bioaerosols. For each sampled exposure event, we randomly selected one CR and one IR to wear a sampling kit.

Surface swab sampling

During each exposure event, a selected object (marker, microphone, or 10.2-inch iPad) used in planned activities was passed between Donors and Recipients. At the end of the exposure event, the object was swabbed for surface sampling before decontamination.

Environmental Interventions and Infection Prevention

The interactions between Donors and Recipients took place in the exposure event room, where controlled environmental conditions were established. Two built-in fan coil units equipped with MERV-8 filters were operational, while we installed dehumidifiers to further regulate environmental factors. We also sealed major uncontrolled air pathways, i.e. windows and doors, prior to the quarantine cohorts.

We continuously monitored CO_2 concentration, indoor air temperature, and relative humidity in

the exposure event room during each exposure event using eight uniformly distributed Aranet4

pro sensors, positioned on the walls at 1.0 and 1.5 meters above the floor, and two sensors

suspended from the ceiling at a height of 2.1 meters. Additionally, we installed two Aranet4 pro

sensors in the hallway near the exposure event room doors at a height of 1.5 meters. Using CO_2

concentration results, we calculated the ventilation rate of the room based on the concentration

decay method [19].

To mitigate the risk of airborne inhalation/transmission outside of the exposure event room, we

converted the entire floor into a quarantine facility through implementing an effective air

cleaning strategy, incorporating 222-nm GUV fixtures and portable HEPA air cleaners in the

hallways, and in-room portable HEPA air cleaners in the rooms other than the exposure event

room (details described previously [20]). We also covered all the bathroom exhausts on the floor

with MERV-16 filters and installed a portable HEPA/carbon filter unit in the bathroom of the

exposure event room. Both Donors and Recipients stayed in assigned individual rooms equipped

with in-room portable HEPA air cleaner and air curtains over the doorways when not

participating in an exposure event. The room used for blood and swab collection was equipped

with a portable HEPA filter, 222-nm GUV, and a local HEPA filtered exhaust for the

participant's breathing zone. Donors and Recipients wore duckbill N95 respirators when outside

of their rooms except during exposure events.

Laboratory Analysis

Digital PCR (dPCR) and Fluorescent Focus Assay

Total nucleic acids were extracted from G-II, mid-turbinate swabs, saliva, surface swabs, and

ambient air samples for viral RNA detection. Influenza A virus RNA was quantified using dPCR.

To assess viral infectivity, we measured fluorescent focus units (FFU) with G-II fine aerosol

samples, mid-turbinate swabs, and surface swabs, adapting a previously described method [7].

<u>Serology</u>

Blood samples were analyzed at the Icahn School of Medicine at Mount Sinai, NY, USA. Serum

samples from all Recipients and Donors were tested in triplicate to assess hemagglutination

inhibition (HAI) antibody titers against influenza virus strains included in the 2023–2024

influenza vaccine: A/Victoria/4897/22 (H1N1), A/Darwin/6/21 (H3N2), and

B/Austria/1359417/21. An enzyme-linked immunosorbent assay (ELISA) was used to assess the

area under the curve (AUC) for binding antibody responses against A/Victoria/4897/22 H1 and

A/Darwin/6/21 H3.

Further details on sample processing, nucleic acid extraction, and assay procedures are provided

in Supplementary Materials, Section V: Supplementary Methods.

Data Analysis

The primary outcome of this study was SAR of influenza virus infections among the Recipients,

including virological confirmation, symptomatic infections, or serological evidence of an

infection.

Descriptive analyses were conducted to summarize the characteristics of both Donors and

Recipients. Violin plots and Loess-smoothed curves were used to visualize viral loads in Donor

samples and their temporal trends. Heatmaps and line plots illustrated maximum individual

symptom score distributions and changes in total symptom scores over time for both Donors and

Recipients. To assess immune responses, HAI titers against vaccine virus strains were plotted to

show changes over time. Line plots were also used to depict environmental factors, including

indoor temperature, relative humidity, and CO_2 concentration. Statistical analyses were done in

R and RStudio.

Ethical Considerations

The study was registered at ClinicalTrials.gov (NCT05666245) and approved by the Intuitional

Review Board of the University of Maryland, Baltimore. All participants provided written

informed consent before enrollment, with assurances of confidentiality and the right to withdraw

at any time without consequence.

Acknowledgments

The authors thank the volunteer participants, hotel staff, and all of the research faculty, fellows,

and student research assistants of the Public Health AeroBiology Lab, the Center for

Sustainability in the Built Environment (City@UMD), the Maryland MEMS & Microfluidics

Lab, and Duncan Lab at the University of Maryland, College Park, as well as the clinical staff

and research nurses at the University of Maryland, Baltimore, for their contributions to volunteer

recruitment, study coordination, sample collection, and laboratory processing (A complete list of

contributors can be found in the Supplementary Materials Section II). We also thank Bill

Lindsley for providing the NIOSH BC-251 bioaerosol samplers used in this project.

This study was supported by NIAID Cooperative agreement U19 grant (5U19AI162130), by the

University of Maryland Baltimore, Institute for Clinical & Translational Research (ICTR) and

the University of Maryland Strategic Partnership: *MPowering the State* (MPower), and by gifts

from The Flu Lab and Balvi Filanthropic Fund.

Author Contributions

Conceptualization: Donald K. Milton, Jelena Srebric, Florian Krammer, Benjamin J. Cowling,

Aubree Gordon

Data Curation: Filbert Hong, Jianyu Lai, Hamed Sobhani

Formal Analysis: Jianyu Lai, Hamed Sobhani

Funding Acquisition: Donald K. Milton, Jelena Srebric, Don L.DeVoe, Wilbur H. Chen, Justin R.

Ortiz, Shuo Chen, Florian Krammer, Benjamin J. Cowling, Aubree Gordon, Yoshihiro Kawaoka,

Gabriele Neumann, Gregory S. Lewis, Arantza Eiguren-Fernandez

Investigation: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H. Sheldon Tai, Filbert Hong,

Isabel Sierra Maldonado, Yi Esparza, Kathleen M. McPhaul, Shengwei Zhu, Juan Manuel

Carreno, Temima Yellin, Jennifer German, Wilbur H. Chen

Project Administration: Filbert Hong, Isabel Sierra Maldonado, Yi Esparza

Software: Filbert Hong

Supervision: Donald K. Milton, Jelena Srebric, Wilbur H. Chen, Florian Krammer

Validation: Filbert Hong, Jianyu Lai, Hamed Sobhani, Temima Yellin, Shengwei Zhu

Visualization: Jianyu Lai, Hamed Sobhani, Isabel Sierra Maldonado

Writing – Original Draft Preparation: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H.

Sheldon Tai, Temima Yellin, Donald K. Milton

Writing – Review & Editing: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H. Sheldon

Tai, Filbert Hong, Isabel Sierra Maldonado, Yi Esparza, Kathleen M. McPhaul, Shengwei Zhu,

Jelena Srebric, Don L. DeVoe, Justin R. Ortiz, Wilbur H. Chen, Shuo Chen, Temima Yellin,

Juan Manuel Carreno, Florian Krammer, Benjamin J. Cowling, Aubree Gordon, and Donald K.

Milton

References

1.   Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza
in the United States: A tool for strengthening influenza surveillance and preparedness.
Influenza Other Respir Viruses **2018**; 12:132–137.

2.   Wong JY, Kelly H, Ip DKM, Wu JT, Leung GM, Cowling BJ. Case fatality risk of
influenza A (H1N1pdm09): a systematic review. Epidemiology **2013**; 24:830–841.

3.   Wong JY, Kelly H, Cheung C-MM, et al. Hospitalization Fatality Risk of Influenza
A(H1N1)pdm09: A Systematic Review and Meta-Analysis. Am J Epidemiol **2015**;
182:294–301.

4.   Wu JT, Ma ESK, Lee CK, et al. The infection attack rate and severity of 2009 pandemic
H1N1 influenza in Hong Kong. Clin Infect Dis **2010**; 51:1184–1191.

5.   Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current
incidents. Nat Rev Microbiol **2005**; 3:591–600.

6.   Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction
number for seasonal, pandemic, and zoonotic influenza: a systematic review of the
literature. BMC Infect Dis **2014**; 14:480.

7.   Yan J, Grantham M, Pantelic J, et al. Infectious virus in exhaled breath of symptomatic
seasonal influenza cases from a college community. Proc Natl Acad Sci USA **2018**;
115:1081–1086.

8.   Benjamin J. Cowling, Dennis K. M. Ip, Vicky J. Fang, et al. Aerosol transmission is an
important mode of influenza A virus spread. Nature Communications **2013**; 4:1935–1935.

9.   World Health Organization. Global technical consultation report on proposed terminology
for pathogens that transmit through the air. 2024. Available at:
https://www.who.int/publications/m/item/global-technical-consultation-report-on-proposed-
terminology-for-pathogens-that-transmit-through-the-air.

10.   Li Y. Basic routes of transmission of respiratory pathogens-A new proposal for
transmission categorization based on respiratory spray, inhalation, and touch. Indoor Air
2021; 31:3–6.

11.   Bueno de Mesquita PJ, Nguyen-Van-Tam J, Killingley B, et al. Influenza A (H3) illness
and viral aerosol shedding from symptomatic naturally infected and experimentally infected
cases. Influenza Other Respir Viruses **2021**; 15:154–163.

12.   Nguyen-Van-Tam JS, Killingley B, Enstone J, et al. Minimal transmission in an influenza
A (H3N2) human challenge-transmission model within a controlled exposure environment.
PLoS Pathog **2020**; 16:e1008704.

13.   Lai J, Mesquita PJB de, Hong F, Ma T, Cowling BJ, Milton DK. Influenza A (H3) viral
aerosol shedding in nasally inoculated and naturally infected cases.
2024; :2024.09.09.24313370. Available at:
https://www.medrxiv.org/content/10.1101/2024.09.09.24313370v2. Accessed 13
September 2024.

14.   Kalliomäki P, Sobhani H, Stratton P, et al. Ozone and ultra-fine particle concentrations in a
hotel quarantine facility during 222 nm far-UVC air disinfection.
2023; :2023.09.29.23296366. Available at:
https://www.medrxiv.org/content/10.1101/2023.09.29.23296366v1. Accessed 10 March
2024.

15.   Lopez CE, Legge KL. Influenza A Virus Vaccination: Immunity, Protection, and Recent
Advances Toward A Universal Vaccine. Vaccines (Basel) **2020**; 8:434.

16.   Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
capture (REDCap)—A metadata-driven methodology and workflow process for providing
translational research informatics support. Journal of Biomedical Informatics **2009**; 42:377–
381.

17.   McDevitt JJ, Koutrakis P, Ferguson ST, et al. Development and Performance Evaluation of
an Exhaled-Breath Bioaerosol Collector for Influenza Virus. Aerosol Sci Technol **2013**;
47:444–451.

18.   Lai J, Coleman KK, Tai SHS, et al. Exhaled Breath Aerosol Shedding of Highly
Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants.
Clin Infect Dis **2023**; 76:786–794.

19.   Batterman S. Review and Extension of CO2-Based Methods to Determine Ventilation
Rates with Application to School Classrooms. Int J Environ Res Public Health **2017**;
14:145.

20.   Sobhani H, Zhu S, Srebric J. Hotels as Quarantine Facilities with Airborne Virus Controls.
Building and Environment **2025**; :112765.

Tables

Table 1. Recipients Demographics

	Cohort 23a		Cohort 24a		Cohort 24b		Cohort 24c		All
	CTL	INT	CTL	INT	CTL	INT	CTL	INT	
Number of participants	3	1	4	4	5	3	2	1	23
Female, N (%)	1 (33)	0 (0)	1 (25)	1 (25)	2 (40)	2 (67)	1 (50)	1 (100)	9 (39)
Age, mean (SD)	38.3 (1.53)	44.0 (-)	39.3 (5.32)	42.0 (8.04)	36.4 (10.5)	29.0 (6.08)	41.0 (4.24)	39.0 (-)	38.0 (7.37)
Vaccinated[a], N (%)	1 (33)	0 (0)	2 (50)	2 (50)	1 (20)	1 (33)	0 (0)	0 (0)	7 (30)
Latino, N (%)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	1 (33)	0 (0)	0 (0)	2 (9)
Race									
Asian, N (%)	0 (0)	1 (100)	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (9)
Black or African American, N (%)	0 (0)	0 (0)	1 (25)	2 (50)	2 (40)	1 (33)	1 (50)	0 (0)	7 (30)

White, N (%)	3 (100)	0 (0)	2 (50)	1 (25)	3 (60)	2 (67)	1 (50)	1 (100)	13 (56)
Other races, N (%)	0 (0)	0 (0)	0 (0)	1 (25)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)

a. Vaccinated against influenza in the past 6 months at the time of entering the quarantine facility.

Table 2. Donor Demographics

	Cohort 24a	Cohort 24b	Cohort 24c	All
Number of participants	1	1	4	6
Female, N (%)	1 (100)	1 (100)	3 (75)	5 (83)
Age, mean (SD)	25.0 (-)	23.0 (-)	20.5 (0.577)	21.7 (1.97)
Latino, N (%)	0 (0)	0 (0)	2 (50)	2 (33)
Race				
Asian, N (%)	0 (0)	1 (100)	0 (0)	1 (17)
Black or African American, N (%)	1 (100)	0 (0)	2 (50)	3 (50)
White, N (%)	0 (0)	0 (0)	2 (50)	2 (33)

Figures

Figure 1. Study design and timeline

Figure 2. Consort diagram for Recipients

Three Recipients from Cohort 23a re-enrolled in 2024. Two initially joined Cohort 24a, but one was discharged before the study began due to a respiratory infection other than influenza and later re-enrolled in Cohort 24c. Another Recipient from Cohort 23a also joined Cohort 24c. As a result, the total number of distinct individuals who entered quarantine was 27, rather than the summed total (31) from each individual cohort.

Figure 3. Consort diagram for Donors

Figure 4. Variations in indoor temperature, relative humidity (RH), and CO_2 concentration in the exposure event room and hallway during cohorts.

Figure 5. Viral RNA load in Donor samples

(a) Violin plots depict the distribution of viral RNA loads (log10 RNA copies) across four

different sample types: breath aerosol <5 µm, breath aerosol ≥5 µm, mid-turbinate swabs, and

aaliva. (b) Loess smoothed curves present the temporal trends of viral RNA loads over the

quarantine period (days) across the sample types, with 95% confidence intervals shaded in gray. (c-f) Line plots illustrate the changes in viral RNA loads over time for each Donor, separated by sample type: breath aerosol <5 µm (c), breath aerosol ≥ 5 µm (d), mid-turbinate swabs (e), and saliva (f).

Figure 6. Infectious viral load in Donor samples

(a) Violin plots depict the distribution of infectious viral loads (log10 FFU) in breath aerosol <5 µm and mid-turbinate swab samples. (b) Loess smoothed curves show the trends in infectious viral loads over the quarantine period (days) for each sample type, with 95% confidence intervals shaded in gray. (c-d) Line plots illustrate the changes in viral RNA loads over time for each Donor, separated by sample type: breath aerosol <5 µm (c) and mid-turbinate swabs (d).

Figure 7. Symptom severity and progression in Donors during quarantine

(a) Heatmap shows the maximum individual symptom scores reported by individual Donors. The color intensity represents the symptom severity, with scores ranging from 0 to 3. Symptoms are listed along the x-axis, and Donors are on the y-axis.

(b) Line plots present total symptom scores over time for each individual Donor. The x-axis represents the days in quarantine, and the y-axis indicates the sum of the above individual symptoms, with each line corresponding to each Donor.

Figure 8. Symptom severity and progression in Recipients during quarantine

(a) Heatmap shows the maximum individual symptom scores reported by individual Recipients.

The color intensity represents the symptom severity, with scores ranging from 0 to 3. Symptoms

are listed along the x-axis, and Donors are on the y-axis.

(b, c) Line plots present total symptom scores over time for Recipients. (b) shows data for the Recipients in cohort 24b, while (c) shows data for those in cohort 24c. The x-axis represents the timeline, with the yellow-shaded areas indicating periods of Donor quarantine. Each subplot corresponds to an individual Recipient, with blue lines representing the control group and green lines representing the intervention group.

HAI titers are shown for Donors (solid lines, filled circles) and Recipients (dot-dashed lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2 (Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1, blue), A/Darwin/6/21 (H3N2, green), and B/Austria/1359417/21 (red). Each facet represents an individual study participant.

Figure 10: HAI titers over time for Donors and Recipients in Cohort 24c

HAI titers are shown for Donors (solid lines, filled circles) and Recipients (dot-dashed lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2 (Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1, blue), A/Darwin/6/21 (H3N2, green), and B/Austria /1359417/21 (red). Each facet represents an individual study participant.